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Abstract
Background Tumor lesions in previously irradiated area may
have a less favorable response to chemotherapy compared to
tumor sites outside the radiation field. The aim of the present
study was to evaluate the response to chemotherapy of locally
recurrent rectal cancer (LRRC) within the previous radiation
field compared to the response of distant metastases outside
the radiation field.
Patients and methods All patients with LRRC referred be-
tween 2000 and 2012 to our tertiary university hospital were
reviewed. The response to chemotherapy of LRRC within
previously irradiated area was compared to the response of
synchronous distant metastases outside the radiation field ac-
cording to the Response Evaluation Criteria in Solid Tumors
(RECIST).
Results Out of 363 cases with LRRC, 29 previously irradiated
patients with distant metastases were treated with chemother-
apy and eligible for analysis. Twenty-six patients (89 %) suf-
fered a first recurrence and three patients (11 %) a second
recurrence. These patients were followed with a median of
22 months (IQR, 9–40 months) and had a median survival
of 33 months (IQR, 14–42). In 23 patients (79 %), the local
recurrence showed stable disease, but the overall response rate
of the local recurrences in the previously irradiated area was
significantly lower than the response rate of distant metastases
outside the radiation field (10 vs. 41 %,p=0.034).
Conclusions Previously irradiated patients with LRRC have a
lower response rate to chemotherapy of the local recurrence
within the radiation field compared to the response rate of
distant metastases outside the radiation field. This suggests
that chemotherapy for local palliation may not have the de-
sired effect.
Keywords Rectal neoplasms . Consolidation chemotherapy .
Palliative care . Neoplasmmetastasis
Introduction
Preoperative short-term radiotherapy (5×5 Gy) has evolved
into an integrated part of the treatment of stage II and III rectal
cancer in The Netherlands, because of the beneficial effect on
local control [1].
Long-term radiotherapy (50 Gy) with or without concomitant
chemotherapy has become standard of care in the treatment of
locally advanced rectal cancer, because of improved local control
and the effect of downsizing/downstaging, thereby facilitating
the possibility of a complete surgical resection [2, 3]. Despite
these advances, still 5–15 % of the patients develop a local re-
currence [4]. The widespread use of neoadjuvant radiotherapy
introduced a new problem: the treatment of locally recurrent
rectal cancer (LRRC) in previously irradiated area.
The treatment of LRRC is a therapeutic challenge. Com-
plete surgical resection is considered the only chance of dura-
ble local control and long-term survival [5, 6]. Unfortunately,
only 31–40 % of the patients with LRRC have resectable
disease [7, 8]. The majority is considered unresectable due
to the presence of extensive synchronous distant metastases
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or an advanced local recurrence in which complete surgical
resection is technically not feasible. These patients can only be
offered palliative treatment, consisting of pelvic radiotherapy
in case of pain or chemotherapy in case of metastasized
disease.
The palliative treatment options in previously irradiated
patients with LRRC are limited. Due to the previous radio-
therapy, only a limited dose of radiation can be administered,
and when treated with chemotherapy, the response of the local
recurrence might be less favorable due to scarring and fibrosis
of the pelvic tissue caused by the previous radiotherapy. This
assumption is supported by a subgroup analysis of a meta-
analysis, evaluating the response to chemotherapy for recur-
rent cervical cancer. Tumor recurrences within the previous
radiation field showed a lower response rate to chemotherapy
compared to the tumor recurrences outside the radiation field
[9]. However, whether this also accounts for LRRC and the
chemotherapeutic regimens used in this disease remains to be
established.
The aim of the present study is to evaluate the response to
chemotherapy of local recurrences in previously irradiated
area compared to the response of distant metastases outside
the radiation field within the same patient.
Patients and methods
All patients with LRRC referred between January 2000 and
December 2012 to the ErasmusMCCancer Institute, a tertiary
Univers i ty hospi ta l for the southwest region of
The Netherlands, were analyzed. Patients were discussed in
a multidisciplinary tumor board to determine the treatment
strategy. At the time of diagnosis of LRRC, all patients were
locally staged by a pelvic computed tomography scan (CT
scan) or by magnetic resonance imaging (MRI) and were
screened for distant metastases by a thoracic and abdominal
imaging. LRRCs were diagnosed by histological biopsies or
by imaging. The criteria for LRRC on imaging were as fol-
lows: a pelvic mass growing on consecutive imaging, a pelvic
mass causing progressive ureter obstruction, or a pelvic mass
with sacral or lateral pelvic bone invasion.
Previously irradiated patients who presented with a first or
second local recurrence with synchronous distant metastases
outside the radiation field were identified. Patients who were
not considered candidates for LRRC surgery and were treated
with chemotherapy were included for analysis. Patients re-
ceiving palliative re-irradiation for local pain relief prior to
chemotherapeutic treatment were excluded, unless re-
irradiation was administered at least 1 year before the start
of the chemotherapeutic treatment and the local recurrence
had grown in size on radiologic imaging. Data were collected
from all referring hospitals and included demographics,
radiotherapeutic reports, pathological reports, radiological im-
aging, and chemotherapeutic information.
Response to chemotherapy was assessed by two experi-
enced medical oncologists and was scored according to Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) version
1.1 [10]. Tumor response was classified as a stable disease
(SD), progressive disease (PD), partial response (PR), or com-
plete response (CR). Overall response rate was defined as the
sum of the patients with a PR or CR. Response evaluation was
assessed after the first available follow-up CT scan after start
of chemotherapy with a minimum of three and a maximum of
nine completed courses of chemotherapy. Baseline CT scan
had to be performed no more than 12 weeks before start of
chemotherapy. Response evaluation of the local recurrence
and the distant metastases was determined separately.
Statistical analysis was carried out using SPSS (version
20.0.0.1). Categorical data were reported as count
(percentage) or median (interquartile range) as appropriate.
Evaluation of distribution of response rates were performed
by a chi-square test and a paired McNemar’s test. p values
<0.05 were considered significant.
Results
A total of 363 patients with LRRC were referred to our hos-
pital; 218 patients (60 %) were not considered candidates for
curative surgery and were offered palliative treatment. One
hundred and seven patients received pelvic irradiation previ-
ously of which 74 had developed synchronous distant metas-
tases outside the previous radiation field. Chemotherapy was
administered to 39 patients. Ten patients were excluded due to
missing data (n=5), additional pelvic radiation within 1 year
before the start of chemotherapy (n=3), and death before tu-
mor response evaluation (n=2), leaving 29 patients evaluable
for analysis (Fig. 1).
Patient and tumor characteristics
Patients and tumor characteristics are outlined in Table 1.
Twenty-six patients (89 %) suffered a first local recurrence,
and three patients (11 %) suffered a second recurrence after
LRRC surgery with curative intent. LRRCwas histopatholog-
ically proven in 16 patients (55 %). The median interval be-
tween primary rectal surgery and LRRC diagnosis was
23 months (IQR, 15–36). Previous pelvic radiotherapy for
the primary tumor or first local recurrence was a long course
radiotherapy (44.6–50 Gy) in 12 patients (41 %), chemoradio-
therapy (50 Gy) in 9 patients (28 %), and a short course ra-
diotherapy (25 Gy) in 8 patients (28 %). The localization of
the distant metastases was pulmonary in 16 patients (55 %),
hepatic in 7 patients (24 %), both pulmonary and hepatic in 3
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patients (10 %), and inguinal lymph nodes in 3 patients
(10 %).
Follow-up and response to chemotherapy
Patients were followed with a median of 22 months (IQR,
9–40). At last follow-up, five patients (17 %) were alive
and 24 patients (82 %) died, resulting in a median survival
of 33 months (IQR, 14–42). The used chemotherapeutic
regimes are depicted in Table 2. Chemotherapy was ad-
ministered after a median of 2 months (IQR, 1–8) after
the diagnosis of LRRC, and response evaluation was done
after a median of 3 cycles. The response rates to chemo-
therapy of the local recurrence and the distant metastases
are outlined separately in Table 3. There was a significant
difference between the overall response rate of local recur-
rence and distant metastases (10 vs. 41 %, p=0.034). On
individual basis, two patients with CR of the distant me-
tastases had PR of the local recurrence. Of 10 patients
with PR of the distant metastases, nine patients had SD
and one had PD of the local recurrence. Of the 10 patients
with SD of the distant metastases, eight patients had SD,
one patient had PD, and one patient had PR of the local
recurrence. Of the seven patients with PD of the distant
metastases, six patients had SD and one patient had PD of
the local recurrence. There was no significant difference in
SD rate of the local recurrences of patients with histolog-
ically proven LRRC or radiologically detected LRRC (88
vs. 70 %, p=0.36).
Discussion
The current study suggests a less favorable response rate (ac-
cording to the RECIST) to chemotherapy of the local recur-
rence in previously irradiated area compared to the response
rates of the distant metastases outside the radiation field within
the same patient. The poor response rates of the local recur-
rences in previously irradiated area suggest that chemothera-
peutic options may not have the desired effect for local
palliation.
The response rate of the local recurrences in previously
irradiated area was 10 %, whereas the 41 % response rate of
the distant metastases was significantly higher. Although there
is little data available about the response to chemotherapy of
LRRC, the poor response is in line with studies evaluating the
potential palliative effect of regional intra-arterial chemother-
apy in LRRC. None of these studies were able to achieve an
acceptable palliative result [11–14]. However, these studies
were all conducted in the 1970s and 1980s before the intro-
duction of the currently used chemotherapeutic regimens and
did not solely included LRRC in previously irradiated area.
Furthermore, the palliative results of these studies were based
on subjective clinical symptoms and not on objective imaging.
To our knowledge, this study is the first to assess the response
of LRRC to contemporary chemotherapeutic regimens and
evaluating the response of the local recurrences and distant
metastases separately.
A possible explanation for the difference in response rate
could be that previous radiotherapy and surgery alter the
Fig. 1 Flowchart of the patients referred to our hospital with LRRC and exclusion of LRRC patients
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environment of the pelvis in which the local recurrence is
located. Previous surgery may affect vascularization of the
pelvic region, and radiotherapy leads to post-irradiation fibro-
sis and subsequently a reduced vascularization. This may pre-
vent adequate local chemotherapeutic tissue levels, which are
necessary to achieve tumor response. A comparable phenom-
enon was found in patients with recurrent cervical carcinoma.
A pooled analysis of patients from multiple randomized con-
trolled trials demonstrated a lower response rate to chemother-
apy of tumor recurrences within the previous irradiated area
compared to tumor recurrences outside the radiation field [9].
However, the analysis included studies comparing the re-
sponse rates of patients with local recurrent disease after pre-
vious radiotherapy to the response rate patients who did not
receive previous radiotherapy. Therefore, these results are
more exposed to patient and tumor biology variability, which
was minimalized in current study by comparing the response
rate of the local recurrence and distant metastases within the
same patient.
A second explanation for the difference in response rate
may be that previous radiotherapy and surgery leads to a very
fibrotic and rigid area, which makes the local recurrence with-
in unable to shrink in contrast to the distant metastases outside
the radiation and operation field. This may explain the remark-
able high number of patients (79 %) with stable disease of the
local recurrence, but not the finding that less patients had
progressive disease of local recurrences in the previously irra-
diated area compared to the distant metastases outside the
radiation field. This suggest that chemotherapy may have
some influence on the local recurrence, but in comparison to
the distant metastases, the response may be different due to
genetic, biological, or environmental differences, whether or
not caused by the radiotherapy.
The high rate of stable disease of the local recurrences
might also be caused by the fact that not all LRRCs were
histologically proven and that we simply evaluated non-
malignant pelvic masses. However, both histologically proven
and radiologically detected LRRCs showed a high rate of
stable disease and we found no difference in stable disease
rate of histologically proven and radiologically detected
LRRCs.
Generally, the prognosis of patients with LRRC is poor.
Moreover, previously irradiated patients with LRRC represent
a group with even a poorer prognosis than Bregular^ not pre-
viously irradiated LRRC. This was demonstrated by an update
of the Dutch TME trial. The vast majority of the patients who
received radiotherapy for the primary tumor had distant me-
tastases at diagnosis or developed them within the first
6 months after diagnosis. This resulted in a very poor median
life expectancy of only 6 months [15]. In the current study, the
survival rate of previously irradiated patients was significantly
longer. Presumably, the patients in the current study are a
selection of patients in generally good clinical condition and
were therefore also considered candidates for chemotherapeu-
tic treatment.
Table 1 Baseline patients and tumor characteristics





Age at diagnosis 65 (38–84)
Primary or LRRC surgery
LAR 15 (52)
APR 11 (38)
Posterior exenteration 2 (7)
Total exenteration 1 (3)
Primary or LRRC resection margin
R0 25 (86)
R1 (≤1 mm) 3 (10)












LAR low anterior resection, APR abdominoperineal resection
Table 2 Chemotherapeutic variables
Number of patients (%)
Total patients 29
Number of cycles 6 (3–31)









Switch to second-line chemotherapy
Yes 12
No 17
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The main therapeutic problems of LRRC are the often
disabling- and difficult to treat symptoms, such as severe pain
and fistulating or bleeding tumors. The low response rate to
chemotherapy as described in the current series clearly stress-
es the high need for novel treatment options and in particular
for those patients with symptomatic local recurrences. Pelvic
re-irradiation can provide pain relief in 65–83 % of the pa-
tients. Unfortunately, the duration of this pain relief is limited
to a median of only 6–9months and it can only be offered for a
limited number of times [16–18]. Moreover, pelvic re-
irradiation leaves distant metastases untreated and probably
does not affect overall survival. A possible mechanism to
improve the response to chemotherapy is to combine it with
hyperthermia. Hyperthermia exposed parts of the body to high
temperatures (42 °C), which causes increased intracellular
drug uptake, enhanced DNA damage, and higher intra-tumor
drug concentrations caused by an increased blood flow [19].
Future research should focus on combining hyperthermia and
chemotherapy to investigate whether this approach improves
the response rates of the local recurrences in previously irra-
diated area.
Chemotherapy is increasingly used in a potential curative
preoperative setting for LRRC. Preoperative chemotherapy is
administered to facilitate tumor downstaging and thus enhanc-
ing the chance of a complete resection. Complete resections
are the most important prognostic factor for overall survival,
and it is hypothesized achieving wider resection margins may
improve outcome [6, 20]. The results of the current study
contradict the potential downstaging effect of chemotherapy
in previously irradiated patients. Therefore, the use of preop-
erative chemotherapy to induce tumor downstaging in previ-
ously irradiated patients needs further investigation.
Due to the retrospective nature of this analysis, this study
has limitations. Moreover, there was no standard policy re-
garding the palliative treatment of patients with LRRC. Che-
motherapy was only considered a suitable option in a small
proportion of the patients with LRRC. This is illustrated by the
fact that only 39 patients out of 74 LRRCs with synchronous
distant metastases were treated with chemotherapy. This re-
sulted in a relative small number of patients eligible for anal-
ysis. Furthermore, different chemotherapeutic regimens were
used in the current study, which could lead to differences in
response rate. However, this potential bias was ruled out by
evaluating the response rate of distant metastases and local
recurrence within the same individual patient.
In palliative treatment of LRRC, chemotherapy is admin-
istered to prolong survival and to achieve local symptom pal-
liation. However, the current study did not evaluate the effect
of chemotherapy on local symptom palliation, because evalu-
ating local palliation is subjective and highly patient- and cli-
nician dependent. Moreover, evaluating local palliation in a
retrospective manner is highly unreliable. By using RECIST,
we were able to evaluate response to chemotherapy in an
objective manner.
In conclusion, previously irradiated patients with LRRC
have a lower response rate to systemic chemotherapy of the
local recurrence within the previous radiation field compared
to the response rates of distant metastases outside the radiation
field. This suggests that chemotherapeutic therapy for local
palliation may not have the desired effect. Further studies
are needed to improve treatment results, for example by com-
bining chemotherapy with hyperthermia.
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